Daily Ards Research Analysis
Analyzed 8 papers and selected 3 impactful papers.
Summary
A large pre-registered randomized trial shows that perioperative nebulized budesonide plus L-cysteine significantly reduces postoperative pulmonary complications, including ARDS, after posterior skull base tumor surgery. Two complementary reviews advance mechanistic and translational thinking: one maps the ARDS ‘cytokine storm’ and precision immunomodulation, while another proposes an NLRP3 inflammasome framework bridging ARDS and cancer for drug repurposing.
Research Themes
- Perioperative prevention of pulmonary complications including ARDS
- Precision immunomodulation guided by ARDS inflammatory subphenotypes
- Inflammasome-driven mechanisms linking ARDS and cancer with translational hypotheses
Selected Articles
1. Perioperative nebulized budesonide and L-Cysteine reduce pulmonary complications after posterior skull base tumor resection: a randomized controlled trial.
In a pre-registered randomized controlled trial of 1,200 posterior skull base tumor surgeries, perioperative nebulized budesonide plus L-cysteine reduced 30-day pulmonary complications (12.3% vs 21.7%). Benefits were consistent across tumor-location subgroups, with the largest effects at the foramen magnum and jugular vein region.
Impact: This large, prospective, registered RCT demonstrates a pragmatic, low-risk intervention that significantly reduces perioperative pulmonary complications including ARDS, offering immediate translational potential.
Clinical Implications: Perioperative inhaled budesonide plus L-cysteine can be considered to reduce 30-day pulmonary complications (including ARDS) after posterior skull base tumor surgery. Implementation should consider local protocols, monitor for steroid-related effects, and evaluate generalizability beyond skull base procedures.
Key Findings
- Perioperative nebulized budesonide plus L-cysteine reduced overall 30-day pulmonary complications versus control (12.3% vs 21.7%, P<0.001).
- Protective effects were consistent across tumor-location subgroups, with the largest reductions at the foramen magnum and jugular vein region.
- Trial was prospectively registered and randomized at a tertiary academic center, supporting methodological rigor.
Methodological Strengths
- Prospective, randomized, pre-registered design with a large sample size (n=1200).
- Clinically meaningful composite primary outcome with predefined subgroup analyses.
Limitations
- Single-center setting may limit generalizability.
- Blinding and adherence details were not reported, which could introduce performance bias.
Future Directions: Multicenter trials to confirm generalizability, dose/timing optimization, safety monitoring (especially steroid-related), cost-effectiveness analyses, and inclusion of patient-centered outcomes.
INTRODUCTION: Perioperative pulmonary complications are a leading cause of morbidity and mortality in patients undergoing Posterior skull base tumors surgery. OBJECTIVE: To evaluate the efficacy and safety of perioperative nebulized inhalation of budesonide combined with L-cysteine in reducing pulmonary complications in patients undergoing surgery for posterior skull base tumors, explore subgroup-specific effects based on tumor location such as the jugular vein region, and identify independent risk factors for pulmonary complications. METHODS: This prospective, randomized, controlled trial was conducted at a tertiary academic medical center between May 1, 2020, and May 1, 2023. The trial was registered in the Chinese Clinical Trial Registry (ChiCTR2000032022) on 2020-04-17 prior to patient recruitment. Patients with posterior skull base tumors scheduled for surgical resection were randomly assigned to either the intervention group or the control group. Patients were stratified into four subgroups based on tumor location: cerebellopontine angle (CPA), clivus, foramen magnum, and jugular vein region. The primary outcome was the incidence of overall pulmonary complications within 30 days postoperatively, including pneumonia, acute respiratory distress syndrome (ARDS), atelectasis, and bronchospasm. Secondary outcomes included the severity of pulmonary complications using Clavien-Dindo classification, length of hospital stay (LOS), intensive care unit (ICU) admission rate, and mortality. RESULTS: A total of 1200 patients with posterior skull base tumors were included in the study. The intervention group had a significantly lower incidence of overall pulmonary complications than the control group (12.3% vs. 21.7%, P < 0.001). Subgroup analysis revealed consistent protective effects across all tumor locations, with the greatest magnitude observed in the foramen magnum subgroup (10.2% vs. 28.3%, P < 0.001) and jugular vein region subgroup (11.0% vs. 26.7%, P < 0.001), followed by the clivus (11.5% vs. 20.1%, P = 0.002) and CPA (13.1% vs. 19.8%, P = 0.012) subgroups. CONCLUSION: Perioperative nebulized inhalation of budesonide combined with L-cysteine was independently associated with a reduced risk of pulmonary complications in patients with posterior skull base tumors, with consistent benefits across all tumor location subgroups.
2. NLRP3 inflammasomes at the ARDS-cancer interface: mechanisms and translational hypotheses.
This narrative review proposes a mechanistic framework linking ARDS and cancer via NLRP3 inflammasomes, arguing that ARDS-driven chronic inflammation may be pro-carcinogenic and that oncologic therapies could elevate ARDS susceptibility. It outlines translational avenues including risk mitigation in cancer care and repurposing of FDA-approved inflammasome-modulating agents.
Impact: By uniting ARDS and oncology through a shared inflammasome axis, this work generates testable translational hypotheses and identifies drug-repurposing opportunities with potential cross-disciplinary impact.
Clinical Implications: While immediate practice change is unlikely, the framework supports risk stratification for ARDS in cancer patients receiving radiotherapy or immunotherapy and motivates trials of inflammasome-targeted interventions.
Key Findings
- Inflammasomes, particularly NLRP3, are pivotal in both ARDS pathogenesis and carcinogenesis, suggesting shared mechanisms.
- ARDS-induced chronic inflammation may foster a tumor-promoting microenvironment.
- Cancer-related inflammasome activity and therapies (radiotherapy, immunotherapy) could increase susceptibility to ARDS.
- The review advances translational hypotheses including prevention strategies and repurposing of FDA-approved drugs.
Methodological Strengths
- Cross-disciplinary synthesis integrating immunology, oncology, and critical care.
- Mechanistic focus that generates concrete, testable translational hypotheses.
Limitations
- Narrative review without systematic search or quantitative synthesis.
- Clinical recommendations are conceptual; direct interventional evidence is lacking.
Future Directions: Prospective cohorts to quantify ARDS risk in oncology settings, biomarker-guided stratification, and early-phase trials of inflammasome-modulating agents to prevent or mitigate ARDS.
Acute respiratory distress syndrome (ARDS) and cancer share common pathogenetic mechanisms that involve immune dysregulation and inflammatory responses. Inflammasomes, part of the initial innate immune response to infection and injury, play a pivotal role in both carcinogenesis and ARDS. Here we review the role of inflammasomes in ARDS and cancer and, in doing so, we find a set of commonalities that allow the proposal of a conceptual framework for their potential intersection that could inform therapeutic development for both conditions. We highlight the importance of understanding how chronic inflammation induced by ARDS may create a microenvironment conducive to carcinogenesis and discuss how cancer-related inflammasome activity and therapies, like radiotherapy and immunotherapy, might increase susceptibility to ARDS. This review paves the way for future work to investigate strategies to prevent ARDS development in cancer and to repurpose FDA-approved drugs for these diseases, alongside preventive measures to reduce the risk of one disease in the presence of the other.
3. Cytokine storm in acute respiratory distress syndrome.
This review synthesizes mechanisms of the ARDS cytokine storm, highlights the hyperinflammatory subphenotype with distinct biomarker profiles and treatment responses, and surveys emerging immunomodulators (IL-1/IL-6 blockade, extracorporeal cytokine removal, nanosponges, MSC/EV therapies). It argues for precision, biomarker-guided care to target injurious inflammation.
Impact: By integrating ARDS subphenotypes with therapeutic strategies, it provides a precision-medicine roadmap connecting mechanistic insight to bedside decision-making.
Clinical Implications: Encourages biomarker-informed identification of hyperinflammatory ARDS and the rational use of immunomodulators alongside lung-protective ventilation and corticosteroids; supports trial designs that stratify by inflammatory subphenotype.
Key Findings
- Hyperinflammatory ARDS subphenotype exhibits distinct biomarkers, worse outcomes, and differential treatment responses.
- Emerging immunomodulatory strategies include IL-1/IL-6 inhibition, extracorporeal cytokine removal, cytokine nanosponges, and MSC/EV-based therapies.
- Precision medicine using biomarker-guided approaches may enable early identification of cytokine storm and selection of targeted therapies.
Methodological Strengths
- Comprehensive synthesis linking mechanistic pathways to clinical phenotypes and therapies.
- Clear articulation of precision-medicine frameworks and therapeutic targets.
Limitations
- Narrative review without systematic search criteria or meta-analysis.
- Therapeutic strategies are proposed based on heterogeneous evidence; limited definitive RCT data.
Future Directions: Prospective validation of biomarker panels, adaptive/stratified RCTs targeting hyperinflammatory ARDS, and rigorous evaluation of safety and efficacy for cytokine-targeting and cell-based therapies.
Acute respiratory distress syndrome (ARDS) is a life-threatening condition characterized by diffuse acute inflammatory lung injury, non-cardiogenic pulmonary edema, and severe hypoxemia. Beyond structural damage, ARDS reflects a profound dysregulation of both innate and adaptive immune responses. Uncontrolled activation of inflammatory pathways disrupts the alveolar-capillary barrier and amplifies cytokine release, which may disseminate systemically as a "cytokine storm." This maladaptive immune response worsens pulmonary injury and contributes to the development of multiorgan dysfunction syndrome (MODS), the leading cause of death in ARDS. This review summarizes current understanding of the cellular and molecular mechanisms underlying "cytokine storm," with emphasis on its systemic effects and its relationship to ARDS subphenotypes, particularly the hyperinflammatory subphenotype, characterized by distinct biomarker profiles, differential treatment responses, and worse outcomes. We also discuss clinical implications and therapeutic strategies, ranging from established interventions such as lung-protective ventilation and corticosteroids to emerging immunomodulatory approaches, including inhibition of interleukin (IL)-1 and IL-6 signaling, extracorporeal cytokine removal, cytokine nanosponges, as well as mesenchymal stromal cell (MSC) and MSC-derived extracellular vesicle therapies. Finally, we emphasize the potential of precision medicine, in which biomarker-guided strategies may allow early identification of patients at risk for a cytokine storm and support the selection of targeted therapies. By aligning treatment with individual inflammatory profiles, these approaches aim to limit immune-mediated organ injury and improve clinical outcomes in ARDS, thereby linking mechanistic insights to patient-centered care.